Lymphoma clinical trials in Idaho

10 actively recruiting lymphoma trials at 10 sites across Idaho.

Data from ClinicalTrials.gov · last refreshed 2026-08-10

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04269902

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Walter Knox Memorial Hospital — Emmett, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05675410

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
Saint Luke's Cancer Institute - Nampa — Nampa, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT07321652

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Idaho Urologic Institute-Meridian — Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06136559

Sites in Idaho:

Saint Alphonsus Regional Medical Center ( Site 0067) — Boise, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04546399

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearran…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06649812

Sites in Idaho:

Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05633615

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
Saint Luke's Cancer Institute - Nampa — Nampa, Idaho
Saint Luke's Cancer Institute - Twin Falls — Twin Falls, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06890884

Sites in Idaho:

Beacon Cancer Care ( Site 0142) — Post Falls, Idaho

View on ClinicalTrials.gov →

Recruiting Network

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT06002828

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
Saint Luke's Cancer Institute - Nampa — Nampa, Idaho
Saint Luke's Cancer Institute - Twin Falls — Twin Falls, Idaho

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Idaho:

Massive Bio SYNERGY-AI site — Boise, Idaho

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10